Clinical predictors of outcome in epithelial ovarian carcinoma

Prognostic and Predictive Factors in Gynecologic Cancers

Volumn , Issue , 2007, Pages 3-14

  Díaz Montes, Teresa P ^a   Bristow, Robert E ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85026271178     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (59)

1. American Cancer Society. Cancer Facts and Figures 2007. http://www.cancer.org/docroot/stt/stt_0.asp.
2. Ries LAG, Eisner MP, Kosary BK, et al, eds SEER Cancer Statistics Review, 1975-2001. Bethesda, MD: National Cancer Institute (http://www.seer.cancer.gov/csr/1975_2001).
3. Burke TW, Morris M. Secondary cytoreductive surgery for ovarian cancer. Obstet Gynecol Clin North Am 1994; 21: 167-78.
4. NIH Consensus Conference: Ovarian cancer: screening, treatment, and follow-up. JAMA 1995; 273: 491.
5. Boente MP, Chi DS, Hoskins WJ. The role of surgery in the management of ovarian cancer: primary and interval cytoreductive surgery. Semin Oncol 1998; 25: 326-34.
6. Norton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 1977; 61: 1307-17.
7. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727-33.
8. Blythe JG, Wahl TP. Debulking surgery: does it increase the quality of survival? Gynecol Oncol 1982; 14: 396-408.
9. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
10. International Federation of Gynecology and Obstetrics Report, 1991: 248.
11. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. J Epidemiol Biostat 2001; 6: 107-38.
12. Berek JS, Hacker NF. Staging and second-look operations in ovarian cancer. In: Alberts DS, Surwit EA, eds. Ovarian Cancer. Boston: Martinus Nijhoff, 1985: 109-27.
13. Young RC, Decker DG, Wharton JT, et al. Staging laparotomy in early ovarian cancer. JAMA 1983; 250: 3072-6.
14. Pecorelli S. FIGO annual report on the results of treatment in gynaecological cancer. J Epidemiol Biostat 1998; 23: 1-168.
15. Munoz KA, Harlan LC, Trimble EL. Patterns of care for women with ovarian cancer in the United States. J Clin Oncol 1997; 15: 3408-15.
16. Heinz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary: FIGO Annual Report. Int J Gynaecol Obstet 2003; 83: 135-66.
17. Guidelines for referral to a gynecologic oncologist: rationale and benefits. The Society of Gynecologic Oncologists. Gynecol Oncol 2000; 78: S1-13.
18. Buchsbaum HJ, Lifshitz S. Staging and surgical evaluation of ovarian cancer. Semin Oncol 1984; 11: 227-37.
19. Knapp RC, Friedman EA. Aortic lymph node metastases in early ovarian cancer. Am J Obstet Gynecol 1974; 119: 1013-17.
20. Guthrie D, Davy ML, Philips PR. A study of 656 patients with ‘early’ ovarian cancer. Gynecol Oncol 1984; 17: 363-9.
21. Earle CC, Schrag D, Neville BA, et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 2006; 98: 172-80.
22. Mayer AR, Chambers SK, Graves E, et al. Ovarian cancer staging: does it require a gynecologic oncologist? Gynecol Oncol 1992; 47: 223-7.
23. Meigs JV. Tumors of the Female Pelvic Organs. New York: McMillan, 1935.
24. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Monogr Natl Cancer Inst 1975; 42: 101-4.
25. Hacker NF, Berek JS, LaGasse LD, et al. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983; 61: 413-20.
26. Hoskins WJ, Rubin SC. Surgery in the treatment of patients with advanced ovarian cancer. Semin Oncol 1991; 18: 213-21.
27. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in smallvolume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992; 47: 159-66.
28. Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994; 170: 974-80.
29. Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 1998; 69: 103-8.
30. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354: 34-43.
31. Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990; 322: 1021-7.
32. Ahmed FY, Wiltshaw E, A’Hern RP, et al. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol 1996; 14: 2968-75.
33. Dembo AJ, Davy M, Steinwig AE, et al. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1990; 75: 263-73.
34. Vergote IB, Kaern J, Abeler VM, et al. Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. Am J Obstet Gynecol 1993; 169: 40-52.
35. Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004; 28: 496-504.
36. Seidman JD, Russell P, Kurman RJ. Surface epithelial tumors of the ovary. In: Kurman RJ, ed. Blaunstein’s Pathology of the Female Genital Tract. New York: Springer-Verlag, 2002: 810-904.
37. Crozier MA, Copeland LJ, Silva EG, et al. Clear cell carcinoma of the ovary: a study of 59 cases. Gynecol Oncol 1989; 35: 199-203.
38. Jenison EL, Montag AG, Griffiths CT, et al. Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. Gynecol Oncol 1989; 32: 65-71.
39. O’Brien ME, Schofield JB, Tan S, et al. Clear cell epithelial ovarian cancer (mesonephroid): bad prognosis only in early stages. Gynecol Oncol 1993; 49: 250-4.
40. Kennedy AW, Markman M, Biscotti CV, et al. Survival probability in ovarian clear cell adenocarcinoma. Gynecol Oncol 1999; 74: 108-14.
41. Tammela J, Geisler JP, Eskew PN Jr, et al. Clear cell carcinoma of the ovary: poor prognosis compared to serous carcinoma. Eur J Gynaecol Oncol 1998; 19: 438-40.
42. Chaitin BA, Gershenson DM, Evans HL. Mucinous tumors of the ovary: a clinicopathologic study of 70 cases. Cancer 1985; 55: 1958-62.
43. Hoerl HD, Hart WR. Primary ovarian mucinous cystadenocarcinomas: a clinicopathologic study of 49 cases with long-term follow-up. Am J Surg Pathol 1998; 22: 1449-62.
44. Kikkawa F, Kawai M, Tamakoshi K, et al. Mucinous carcinoma of the ovary: clinicopathologic analysis. Oncology 1996; 53: 303-7.
45. Sainz de la Cuesta R, Eichhorn JH, Rice LW, et al. Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Gynecol Oncol 1996; 60: 238-44.
46. Le T, Krepart GV, Lotocki RJ, et al. Malignant mixed mesodermal ovarian tumor treatment and prognosis: a 20-year experience. Gynecol Oncol 1997; 65: 237-40.
47. Andersen WA, Young DE, Peters WA, et al. Platinum-based combination chemotherapy for malignant mixed mesodermal tumors of the ovary. Gynecol Oncol 1989; 32: 319-22.
48. Boucher D, Tetu B. Morphologic prognostic factors of malignant mixed mullerian tumors of the ovary: a clinicopathologic study of 15 cases. Int J Gynecol Pathol 1994; 13: 22-8.
49. Dehner LP, Norris HJ, Taylor HB. Carcinosarcomas and mixed mesodermal tumors of the ovary. Cancer 1971; 27: 207-16.
50. Kaern J, Trope CG, Kristensen GB, et al. Evaluation of deoxyribonucleic acid ploidy and S-phase fraction as prognostic parameters in advanced epithelial ovarian carcinoma: a prospective study. Am J Obstet Gynecol 1994; 170: 479-87.
51. Zanetta G, Keeney GL, Cha SS, et al. Flow cytometric analysis of DNA content in advanced ovarian carcinoma: its significance to long-term survival. Am J Obstet Gynecol 1996; 175: 1217-25.
52. Gajewski WH, Fuller AF Jr, Pastel-Ley C, et al. Prognostic significance of DNA content in epithelial ovarian cancer. Gynecol Oncol 1994; 53: 5-12.
53. Canney PA, Moore M, Wilkinson PM, James RD. Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer 1984; 50: 765-9.
54. Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 2000; 82: 1535-8.
55. Makar AP, Kristensen GB, Kaern J, et al. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Obstet Gynecol 1992; 79: 1002-10.
56. Mogensen O. Prognostic value of CA 125 in advanced ovarian cancer. Gynecol Oncol 1992; 44: 207-12.
57. Thigpen T, Brady MF, Omura GA, et al. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer 1993; 71: 606-14.
58. Omura GA, Brady MF, Homesley HD, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991; 9: 1138-50.
59. Loizzi V, Chan JK, Osann K, et al. Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am J Obstet Gynecol 2003; 189: 1301-7.